^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

ALK negative

i
Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Entrez ID:
3d
PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)
P1, N=12, Terminated, Henan Cancer Hospital | Phase classification: P1/2 --> P1 | Trial completion date: Feb 2025 --> Aug 2025
Phase classification • Trial completion date
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK negative
|
Epidaza (chidamide) • parsaclisib (INCB50465)
15d
Clinicopathological Features and Immunochemical Staining of Inflammatory Myofibroblastic Tumor: A Retrospective Study of 48 Cases. (PubMed, Anal Cell Pathol (Amst))
For desmin and cytokeratin, the results differed among cases and may not be used as determinant factors to diagnose such diseases. We hope that this investigation will be a cornerstone for further studies on the diagnosis of IMT in the absence of ALK rearrangements.
Retrospective data • Journal
|
ALK (Anaplastic lymphoma kinase) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD34 (CD34 molecule) • ANO1 (Anoctamin 1)
|
ALK positive • ALK rearrangement • ALK negative
17d
Anaplastic large cell lymphoma in the penis: a case report and review of literature. (PubMed, J Med Case Rep)
This case highlights the diagnostic challenge posed by rare penile lesions and, more importantly, the therapeutic dilemma of selecting an appropriate treatment for a disease that is localized yet multifocal. The successful outcome with systemic brentuximab vedotin plus cyclophosphamide, doxorubicin, vincristine, and prednisone therapy, a deviation from standard guidelines for unifocal primary cutaneous anaplastic large cell lymphoma, underscores the need for individualized treatment strategies and further research to establish risk-adapted guidelines for this rare clinical entity.
Review • Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression • ALK negative
|
doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin) • vincristine • prednisone
18d
Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • PTEN (Phosphatase and tensin homolog) • PI3K (Phosphoinositide 3-kinases)
|
ALK rearrangement • EGFR wild-type • KRAS wild-type • RAS wild-type • ALK negative
|
docetaxel • Tyvyt (sintilimab) • albumin-bound paclitaxel • afuresertib (LAE002)
18d
Anaplastic lymphoma kinase-negative inflammatory myofibroblastic tumor of the appendix and ileocecal region: a rare clinical entity. (PubMed, J Surg Case Rep)
Surgical resection remains the mainstay of treatment. This case highlights the importance of including IMT in the differential diagnosis of atypical intra-abdominal masses and supports the role of advanced molecular techniques in improving diagnostic accuracy and management.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK negative
20d
ALK-Negative Anaplastic Large Cell Lymphoma With Rare Scalp Involvement: A Case Report and Literature Review. (PubMed, J Investig Med High Impact Case Rep)
Histopathological analysis confirmed lymphoma with atypical large cells, and immunohistochemistry showed that both ALK and CD30 were negative, making the diagnosis atypical. This case illustrates the rarity of scalp involvement in ALK-negative ALCL and underscores the importance of a multidisciplinary approach, integrating clinical, imaging, and histological findings for accurate diagnosis and management.
Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK negative
21d
P30CA033572: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (clinicaltrials.gov)
P2, N=48, Active, not recruiting, City of Hope Medical Center | Trial completion date: Aug 2025 --> Jul 2026
Trial completion date
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • TNFRSF8 positive • ALK negative
|
doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • daunorubicin
24d
Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort study. (PubMed, Lung Cancer)
These findings suggest that P-combo showed a durable survival advantage over monotherapy and acceptable TRAEs in patients with PD-L1-positive NSCLC, identifying clinical subgroups most likely to benefit. Prospective randomized trials are warranted to validate these observations and guide optimal first-line treatment strategies.
Journal
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • ALK negative
|
Keytruda (pembrolizumab)
30d
Inflammatory Myofibroblastic Tumor of Adults ≥40 Years: A Clinicopathologic Study of 34 Cases. (PubMed, Am J Surg Pathol)
IMTs may arise in adulthood and mostly manifest in visceral sites. Despite earlier reports, ALK is frequently expressed/rearranged in tumors in this age group.
Journal
|
ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • TIMP3 (TIMP Metallopeptidase Inhibitor 3)
|
ALK positive • ALK rearrangement • ALK fusion • ALK negative
1m
A prospective, single-center, single-arm clinical study evaluating the efficacy and safety of pralatrexate combined with chidamide and azacitidine in adult patients with newly diagnosed peripheral T-cell lymphoma (ChiCTR2500109351)
P2, N=20, Not yet recruiting, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
New P2 trial
|
ALK negative
|
azacitidine • Epidaza (chidamide) • Folotyn (pralatrexate)
1m
New P2 trial • IO biomarker
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • STK11 (Serine/threonine kinase 11)
|
KRAS G12D • STK11 mutation • KRAS G12 • ALK negative
1m
Aberrant TTF1 expression in anaplastic large cell lymphoma (PubMed, Arkh Patol)
The study demonstrated for the first time the possibility of aberrant expression of TTF1 by anaplastic large cell lymphoma cells. In one case, intense expression of TTF1 was observed in 100% of tumor cells, in the rest - in no more than 15%. Moreover, expression was observed both in cases of using clone SP141 and clone SPT24. In our opinion, the identified aberrant expression of TTF1 in anaplastic large cell lymphoma, may cause an error in the morphological diagnosis of the metastatic process and requires additional attention from the pathologist.
Journal
|
ALK (Anaplastic lymphoma kinase) • TTF1 (Transcription Termination Factor 1) • NKX2-1 (NK2 Homeobox 1)
|
ALK negative